Brentuximab vedotin as monotherapy for unresectable breast implant‐associated anaplastic large cell lymphoma. Issue 5 (11th April 2019)

• Record Type: Journal Article
• Authors: Stack, Anthony; Levy, Isaac
• Is Part Of: Clinical case reports. Volume 7:Issue 5(2019)
• Page Start: 1003
• Page End: 1006
• Publication Date: 2019-04-11
• Subjects: ALCL -- breast implant‐associated anaplastic large cell lymphoma -- breast lymphoma -- brentuximab vedotin -- lymphoma; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.2142
• Languages: English
• ISSNs: 2050-0904

Abstract

Key Clinical Message: BI‐ALCL is a rare CD30+ T‐cell malignancy, which is known to complicate textured breast implants. The CD30‐targeting immunoconjugate, brentuximab vedotin, has been suggested for invasive BI‐ALCL; however, its efficacy for unresectable BI‐ALCL has not been demonstrated. We present a case of unresectable BI‐ALCL, which was successfully treated with brentuximab vedotin. Abstract : BI‐ALCL is a rare CD30+ T‐cell malignancy, which is known to complicate textured breast implants. The CD30‐targeting immunoconjugate, brentuximab vedotin, has been suggested for invasive BI‐ALCL; however, its efficacy for unresectable BI‐ALCL has not been demonstrated. We present a case of unresectable BI‐ALCL, which was successfully treated with brentuximab vedotin.